Actuate Therapeutics Raises $9.96 Million in Stock-and-Warrant Offering
Actuate Therapeutics (ACTU) raised $9.96M via a stock-and-warrant offering with Newbridge Securities. The deal included 30.99M shares and warrants for 15.49M more, with a 45-day over-allotment option. Broadridge was appointed to administer the warrants.
How this was made

The 30-second read
Why it matters
The offering adds ~31 million shares and warrants to the float, increasing dilution risk and likely prompting a near‑term price dip.
Market read
A micro‑cap biotech raising ~10 M USD is a primary corporate action but limited in market impact; traders may short on dilution risk.
What to watch
Potential strategic partnership with Newbridge Securities or use of proceeds for pipeline acceleration.
Background
Actuate Therapeutics is a clinical‑stage biotech that filed an 8‑K announcing the offering and appointed Broadridge as warrant agent.
Ticker impact
Actuate Therapeutics disclosed a $9.96 million public stock‑and‑warrant offering, the first report of this capital raise.
downward pressure as the market prices in the dilution
A fresh secondary offering increases share supply; investors typically react with a sell‑off until the proceeds are deployed.
Market effects
Minimal; the raise is specific to Actuate and does not signal broader biotech financing trends.
None; the company is US‑listed and the amount is modest.
Low; the disclosure is unlikely to affect global market sentiment.
Counterpoint
If the capital is earmarked for a breakthrough trial, the long‑term upside could outweigh short‑term dilution concerns.
Key entities
- companyActuate Therapeutics
Biotech issuer of the stock‑and‑warrant offering.
- underwriterNewbridge Securities
Lead underwriter for the offering.
- service providerBroadridge Corporate Issuer Solutions
Appointed warrant agent for the new warrants.
